1. Home
  2. Live Updates
  3. Prnewswire servier

Live Breaking News & Updates on Prnewswire servier

Stay informed with the latest breaking news from Prnewswire servier on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Prnewswire servier and stay connected to the pulse of your community

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France , United-states , Canada , Switzerland , Australia , Brazil , United-kingdom , Boston , Massachusetts , Suresnes , France-general- , Israel

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma

/PRNewswire/ -- Servier, a global leader in oncology focused on delivering meaningful therapeutic progress for the patients it serves, today announced the FDA...

France , Australia , Suresnes , France-general- , Switzerland , Israel , Brazil , United-kingdom , Boston , Massachusetts , United-states , Canada

Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023

Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Boston , Massachusetts , United-states , American , Nathan-mellor , Prnewswire-servier , Becky-martin , Arjun-prasad , Servier-pharmaceuticals , European-union , Servier-group , American-society-of-hematology

Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023

/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will be presenting new data in acute...

United-states , Boston , Massachusetts , American , Arjun-prasad , Prnewswire-servier , Becky-martin , Nathan-mellor , American-society-of-hematology , Servier-group , European-union , Servier-pharmaceuticals

New Vorasidenib Data at SNO 2023 Bolster Servier's Neuro-Oncology Clinical Development Program

/PRNewswire/ -- Servier will showcase new data from its vorasidenib clinical development program in a plenary townhall at the 28th Annual Meeting of the...

United-states , Boston , Massachusetts , Vancouver , British-columbia , Canada , American , Susan-pandya , Prnewswire-servier , Katherineb-peters , Patrick-wen , Nathan-mellor

Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in the Treatment of IDH1-mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)

Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in the Treatment of IDH1-mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Singapore , Massachusetts , United-states , Boston , Australia , Macao , Macau-general- , Macau , Hong-kong , Taiwan , China , Susan-pandya

Servier Presents Updated Results for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes at the 2023 European Hematology Association (EHA) Congress

/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced updated data from the...

Texas , United-states , Australia , Hong-kong , Boston , Massachusetts , Macao , Macau-general- , Macau , China , Germany , Singapore

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma

Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2...

Boston , Massachusetts , United-states , American , Nathan-mellor , Ingok-mellinghoff , Susan-pandya , Ingo-mellinghoff , Prnewswire-servier , Brock-greene , Memorial-sloan-kettering-cancer-center , Servier-pharmaceuticals

Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma

/PRNewswire/ -- Servier, a global pharmaceutical group, today announced that the European Commission (EC) has approved Tibsovo® (ivosidenib tablets) as a...

Hong-kong , United-kingdom , Singapore , Nigeria , France , United-states , China , Alfa , Nigeria-general- , Brazil , Macau , Paris

Servier achieves the Best Place to Work certification in Bulgaria for 2023

/PRNewswire/ -- Servier, a leading independent multinational pharmaceutical company focusing on oncology and chronic cardio metabolic diseases, has been...

Sofia , Sofiya-grad , Bulgaria , Prnewswire-servier , Antoaneta-nestorova , Emilio-gagliardi , Twitter , Linkedin , Facebook , Platinum-standard- , General-manager , Servier-bulgaria